AU6259586A - Novel plasmid containing TNF gene and use thereof - Google Patents

Novel plasmid containing TNF gene and use thereof

Info

Publication number
AU6259586A
AU6259586A AU62595/86A AU6259586A AU6259586A AU 6259586 A AU6259586 A AU 6259586A AU 62595/86 A AU62595/86 A AU 62595/86A AU 6259586 A AU6259586 A AU 6259586A AU 6259586 A AU6259586 A AU 6259586A
Authority
AU
Australia
Prior art keywords
tnf
plasmid
plasmid containing
base sequence
dna fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU62595/86A
Other versions
AU597902B2 (en
Inventor
Shigekazu Matsukura
Takehiro Oshima
Shoji Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of AU6259586A publication Critical patent/AU6259586A/en
Application granted granted Critical
Publication of AU597902B2 publication Critical patent/AU597902B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/31—Linker sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides a vector plasmid capable of efficient tumor necrosis factor (TNF) production, a process capable of efficient TNF production in a host transformed with said plasmid and a composition containing the TNF produced by said process.The novel plasmid of the present invention is characterized by having inserted therein a DNA fragment that has a phage-derived promoter region upstream of a structural gene for TNF and in which a DNA fragment containing an E. coli gene-derived transcription termination coding base sequence (terminator) is joined immediately downstream of a base sequence coding for the termination of translation of said structural gene.
AU62595/86A 1985-09-30 1986-09-11 Novel plasmid containing TNF gene and use thereof Ceased AU597902B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP60-217740 1985-09-30
JP60217740A JPH0698004B2 (en) 1985-09-30 1985-09-30 Novel plasmid for TNF expression

Publications (2)

Publication Number Publication Date
AU6259586A true AU6259586A (en) 1987-04-02
AU597902B2 AU597902B2 (en) 1990-06-14

Family

ID=16709008

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62595/86A Ceased AU597902B2 (en) 1985-09-30 1986-09-11 Novel plasmid containing TNF gene and use thereof

Country Status (7)

Country Link
US (1) US4871663A (en)
EP (1) EP0220482B1 (en)
JP (1) JPH0698004B2 (en)
KR (1) KR870003201A (en)
AT (1) ATE70305T1 (en)
AU (1) AU597902B2 (en)
DE (1) DE3682872D1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686455B1 (en) * 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
ATE73856T1 (en) * 1984-12-21 1992-04-15 Biogen Inc PURIFICATION, PREPARATION AND USE OF TUMOR NECROSIS FACTORS.
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
CA1340998C (en) * 1986-02-04 2000-05-23 Den'ichi Mizuno Dnas and processes for their preparation, novel plasmids possessing them, novel polypeptides and processes for their preparation and novel anti-tumor agents comprising said polypeptides
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US6410241B1 (en) 1999-03-24 2002-06-25 Board Of Regents, The University Of Texas System Methods of screening open reading frames to determine whether they encode polypeptides with an ability to generate an immune response
ES2347239T3 (en) 2002-12-02 2010-10-27 Amgen Fremont Inc. ANTIBODIES DIRECTED TO THE TUMOR NECROSIS FACTOR AND USES OF THE SAME.
JP2005132795A (en) * 2003-10-31 2005-05-26 Genichiro Soma Anti-malignant gliomatous agent and anti-malignant gliomatous agent for animal
US7479540B1 (en) 2003-12-22 2009-01-20 Chandan Prasad Adipomodulin and related molecules and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3582183D1 (en) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co DNS ENCODING THE HUMAN TUMORNIC CROSIS FACTOR AND THE HUMAN TUMORNIC CRISIS FACTOR POLYPEPTIDE.
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
ATE73856T1 (en) * 1984-12-21 1992-04-15 Biogen Inc PURIFICATION, PREPARATION AND USE OF TUMOR NECROSIS FACTORS.

Also Published As

Publication number Publication date
US4871663A (en) 1989-10-03
EP0220482A1 (en) 1987-05-06
EP0220482B1 (en) 1991-12-11
JPS6277324A (en) 1987-04-09
ATE70305T1 (en) 1991-12-15
KR870003201A (en) 1987-04-15
AU597902B2 (en) 1990-06-14
JPH0698004B2 (en) 1994-12-07
DE3682872D1 (en) 1992-01-23

Similar Documents

Publication Publication Date Title
ES8703490A1 (en) DNA encoding human tumor necrosis factor and human tumor necrosis factor polypeptide.
EP1502952A3 (en) Process for the production of protein products in Aspergillus oryzae and a promoter for use in Aspergillus
US4578355A (en) Plasmid cloning vector pAS1
IL68790A (en) Polydeoxyribonucleotide coding for ifn-alpha2(arg),plasmid containing it,cloning of said plasmid and microorganisms containing it and ifn-alpha(arg)encoded by said polydeoxyribonucleotide and its preparation
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
AU6893587A (en) Recombinant dna sequences, vectors containing them and method for the use thereof
EP0048970A3 (en) Polypeptides, process for their microbial production, intermediates therefor and compositions containing them
AU556761B2 (en) Vector for corne- or brevi-bacterial hosts
ES8401133A1 (en) Construction of DNA sequences and their use for microbial production of proteins, in particular human serum albumin.
KR830005355A (en) Method for synthesizing various polypeptides in bacterial host and polypeptide DNA
GR3006178T3 (en)
KR830005350A (en) Method for producing fusion protein and eukaryotic protein for surface conjugate
YU113285A (en) Process for making necrosis tumor factor from mixture with other proteins
IE872455L (en) Improved recombinant expression
AU6259586A (en) Novel plasmid containing TNF gene and use thereof
AU606584B2 (en) DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
Miozzari et al. Gene fusion during the evolution of the tryptophan operon in Enterobacteriaceae
EP0146026A3 (en) Dna encoding rabbit tnf, vector having said dna inserted thereinto, host transformed with said vector, rabbit tnf polypeptide, and process for production thereof
PT97383A (en) Process for the production of a globin chain, a binding fragment thereof and haemoglobin, and haemoglobin compositions
EP0139501A3 (en) The manufacture and expression of genes for thaumatin
IE831099L (en) Cloning vehicles for polypeptide expression in microbial¹hosts
IE53607B1 (en) Expression vectors
Moore et al. Nucleotide sequence of the argF regulatory region of Escherichia coli K-12
EP0422217A4 (en) Human recombinant placental ribonuclease inhibitor and method of production
EP0681027A2 (en) Plasmid vector and its use for the production of heterologous proteins

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired